HSK-44459

Primary objective: To evaluate the safety and tolerability of HSK44459 tablets after single and multiple administration in healthy subjects. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of HSK44459 tablets after single and multiple administration in healthy subjects; 2. To evaluate the effect of food on the pharmacokinetics of HSK44459 tablets after single administration. Exploratory objectives 1. To preliminarily explore the metabolites and main excretion pathways of HSK44459 in humans, and investigate the cumulative excretion rate of HSK44459 parent drug and metabolites (if applicable) in urine and feces; 2. To explore the pharmacodynamic (PD) characteristics of HSK44459 tablets after single and multiple administration in healthy subjects; 3. To preliminarily evaluate the effect of HSK44459 tablets on the QT interval. The effect of pharmacokinetics after single administration.

Primary purpose: To preliminarily evaluate the effectiveness of HSK44459 tablets in subjects with idiopathic pulmonary fibrosis; Secondary purpose: To evaluate the safety of HSK44459 tablets in subjects with idiopathic pulmonary fibrosis; To evaluate the pharmacokinetic (PK) characteristics of HSK44459 tablets in subjects with idiopathic pulmonary fibrosis.